Haemonetics Co. (NYSE:HAE) Short Interest Down 6.4% in March

Haemonetics Co. (NYSE:HAE) saw a large decline in short interest in the month of March. As of March 31st, there was short interest totalling 2,040,000 shares, a decline of 6.4% from the March 15th total of 2,180,000 shares. Approximately 4.1% of the shares of the company are short sold. Based on an average daily trading volume, of 455,600 shares, the short-interest ratio is currently 4.5 days.

Haemonetics Price Performance

Shares of HAE stock opened at $84.88 on Thursday. The stock’s fifty day simple moving average is $78.72 and its 200 day simple moving average is $82.77. The company has a debt-to-equity ratio of 0.91, a current ratio of 2.92 and a quick ratio of 1.76. The firm has a market cap of $4.31 billion, a price-to-earnings ratio of 34.50, a P/E/G ratio of 2.01 and a beta of 0.36. Haemonetics has a one year low of $70.74 and a one year high of $95.26.

Haemonetics (NYSE:HAE) last announced its quarterly earnings results on Thursday, February 8th. The medical instruments supplier reported $1.04 EPS for the quarter, beating the consensus estimate of $0.94 by $0.10. The business had revenue of $336.20 million for the quarter, compared to analyst estimates of $320.84 million. Haemonetics had a return on equity of 22.37% and a net margin of 9.97%. Haemonetics’s quarterly revenue was up 10.1% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.85 EPS. On average, analysts expect that Haemonetics will post 3.95 earnings per share for the current fiscal year.

Institutional Trading of Haemonetics

Several institutional investors have recently bought and sold shares of HAE. American Century Companies Inc. boosted its stake in Haemonetics by 163.5% in the 1st quarter. American Century Companies Inc. now owns 17,407 shares of the medical instruments supplier’s stock valued at $1,100,000 after buying an additional 10,802 shares in the last quarter. PNC Financial Services Group Inc. boosted its stake in Haemonetics by 3.1% in the first quarter. PNC Financial Services Group Inc. now owns 12,802 shares of the medical instruments supplier’s stock worth $809,000 after purchasing an additional 387 shares in the last quarter. Bank of Montreal Can boosted its stake in Haemonetics by 300.3% in the first quarter. Bank of Montreal Can now owns 33,039 shares of the medical instruments supplier’s stock worth $2,033,000 after purchasing an additional 24,785 shares in the last quarter. Rhumbline Advisers boosted its stake in Haemonetics by 1.9% in the first quarter. Rhumbline Advisers now owns 148,770 shares of the medical instruments supplier’s stock worth $9,405,000 after purchasing an additional 2,817 shares in the last quarter. Finally, Commonwealth of Pennsylvania Public School Empls Retrmt SYS boosted its stake in Haemonetics by 10.6% in the first quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 18,732 shares of the medical instruments supplier’s stock worth $1,184,000 after purchasing an additional 1,788 shares in the last quarter. Institutional investors and hedge funds own 99.67% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have recently issued reports on HAE. TheStreet cut Haemonetics from a “b-” rating to a “c+” rating in a research report on Thursday, February 29th. Barrington Research restated an “outperform” rating and set a $105.00 price objective on shares of Haemonetics in a research report on Friday, April 12th. Finally, StockNews.com cut Haemonetics from a “buy” rating to a “hold” rating in a research report on Friday, March 22nd.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system, and Donor360.